Bedrijfstakpensioenfonds Voor DE Media PNO Sells 6,600 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Bedrijfstakpensioenfonds Voor DE Media PNO reduced its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 8.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,150 shares of the medical equipment provider's stock after selling 6,600 shares during the period. Intuitive Surgical comprises 3.4% of Bedrijfstakpensioenfonds Voor DE Media PNO's portfolio, making the stock its 6th largest position. Bedrijfstakpensioenfonds Voor DE Media PNO's holdings in Intuitive Surgical were worth $25,553,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in ISRG. OFI Invest Asset Management bought a new stake in shares of Intuitive Surgical in the third quarter worth $25,000. Baystate Wealth Management LLC increased its stake in shares of Intuitive Surgical by 150.0% in the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider's stock worth $25,000 after buying an additional 45 shares during the last quarter. MCF Advisors LLC increased its stake in shares of Intuitive Surgical by 108.1% in the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider's stock worth $26,000 after buying an additional 40 shares during the last quarter. Headinvest LLC bought a new stake in shares of Intuitive Surgical in the third quarter worth $28,000. Finally, Able Wealth Management LLC bought a new stake in shares of Intuitive Surgical in the fourth quarter worth $28,000. 83.64% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Intuitive Surgical news, VP Marshall Mohr sold 108,790 shares of the business's stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the sale, the vice president now owns 26,877 shares in the company, valued at approximately $10,349,795.16. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, VP Marshall Mohr sold 108,790 shares of the company's stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total value of $41,892,853.20. Following the transaction, the vice president now owns 26,877 shares in the company, valued at approximately $10,349,795.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Gary S. Guthart sold 24,325 shares of the company's stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $376.06, for a total value of $9,147,659.50. Following the completion of the transaction, the chief executive officer now owns 9,425 shares in the company, valued at approximately $3,544,365.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 249,418 shares of company stock worth $96,300,959. Company insiders own 0.90% of the company's stock.

Analyst Ratings Changes

ISRG has been the subject of several recent research reports. Stifel Nicolaus boosted their target price on shares of Intuitive Surgical from $420.00 to $430.00 and gave the company a "buy" rating in a research note on Monday, April 8th. Mizuho boosted their target price on shares of Intuitive Surgical from $350.00 to $390.00 and gave the company a "neutral" rating in a research note on Thursday, January 25th. Jefferies Financial Group boosted their target price on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a "hold" rating in a research note on Friday, April 19th. Barclays boosted their price target on shares of Intuitive Surgical from $385.00 to $430.00 and gave the company an "overweight" rating in a report on Thursday, January 25th. Finally, Piper Sandler boosted their price target on shares of Intuitive Surgical from $425.00 to $435.00 and gave the company an "overweight" rating in a report on Friday, April 19th. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $396.17.

Intuitive Surgical Trading Up 0.6 %

ISRG stock traded up $2.21 during trading on Friday, hitting $375.33. The company had a trading volume of 927,845 shares, compared to its average volume of 1,564,565. The firm has a market capitalization of $133.13 billion, a price-to-earnings ratio of 67.75, a P/E/G ratio of 4.82 and a beta of 1.36. The business has a 50 day moving average of $386.19 and a 200 day moving average of $346.29. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $403.76.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The business had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. During the same quarter in the prior year, the company posted $1.00 earnings per share. The company's quarterly revenue was up 11.5% compared to the same quarter last year. As a group, equities analysts predict that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.